The global autologous cell therapy market size was valued at USD 5.1 billion in 2021 and is anticipated to grow at a compound annual growth rate (CAGR) of 19.4% during the forecast period from 2022 to 2030. Some of the key factors driving the market growth include numerous immunological advantages, a rise in the proportion of the geriatric population across the globe, and a reduced risk of autologous cell therapy rejection. Autologous cell therapy is widely used in a range of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, orthopedics, wound healing, and others.
Due to COVID-19, the autologous cell therapy market was significantly affected by the less inflow of patients due to restrictions on movement imposed by various governments across the world. Alternatively, during the initial phase of the COVID-19 outbreak, the majority of clinical trials were on hold however the post COVID-19 the hospitals and clinics have witnessed patient flow for clinical or cell therapy applications.
In terms of revenue, the bone marrow segment dominated the market with a share of over 42.9% in 2021. Based on sources, the autologous cell therapy market is segmented into bone marrow, epidermis, mesenchymal stem cells, haematopoietic stem cells, chondrocytes, and others. The bone marrow in autologous cell therapy is been successfully used to treat different diseases. It is one of the major sources used for cell therapy where the patient’s healthy stem cells are collected from the bone marrow or blood before treatment stored. Alternatively, autologous cell therapy with bone marrow provides certain benefits over a donor’s stem cells.
The mesenchymal stem cells segment is anticipated to witness the fastest growth over the forecast period owing to their preclinical and clinical applications in tissue regeneration to therapy for immune diseases. For instance, in March 2020, the Celltex Therapeutics Corporation announced that it has begun active discussions with the FDA regarding a study using of MSCs against COVID-19 symptoms. In addition, the company has researched the safety and efficiency of the use of MSCs for patients suffering from injuries, pain, and maladies associated with vascular, autoimmune, and other debilitating including inflammatory lung conditions, chronic obstructive pulmonary disease (COPD), and pneumonia.
In terms of revenue, the cancer segment dominated the market with a share of over 20.7% in 2021. Based on application, the market is segmented into cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, orthopedics, wound healing, and others. According to WHO (World Health Organization), cancer disease accounts for nearly 10 million deaths in 2020.
As per the American Cancer Society, in 2021, 1.9 million new cancer cases were diagnosed and 608,570 cancer deaths in the U.S. Autologous cell therapy is anticipated to find its major demand in cancer application with the growing burden of cases and demand for treatment and therapy. In August 2022, Anixa Biosciences mentioned that it has administered the first dose of its follicle-stimulating hormone receptor (FSHR)- targeted autologous cell therapy to an ovarian cancer patient in a Phase I trial.
In terms of revenue, the hospitals & clinics segment dominated the market with a share of over 45.9% in 2021. Based on end use, the market is segmented into hospitals & clinics, ambulatory centers, academics & research, and others. The increasing burden of cancer, autoimmune diseases, cardiovascular diseases, and neurodegenerative disorders have led to the rising requirement for treatment and therapies.
The academics & research segment is anticipated to witness growth at a CAGR of 20.8% over the estimated timeframe. Autologous cell therapy is garnering an increasing amount of interest worldwide and is being extensively studied. It is an emerging field of science that uses the living cellular to treat and prevent disease. Academics and research mostly conduct research in bone marrow, epidermis, mesenchymal stem cells, haematopoietic stem cells, and chondrocytes. For instance, in October 2022, Allogene Therapeutics mentioned the new survey of the U.S academic institutes that specialized in the administration of CAR T, which discovered 82% of respondents agreed that CAR T therapies have assisted in the management of cancers.
North America dominated the autologous cell therapy market with a revenue share of 41.9% in 2021. The market in this region is highly competitive since most of the major market players such as BrainStorm Cell Therapeutics, Bristol Myers Squibb is operating in this region. Furthermore, the growing burden of the geriatric population, numerous immunological advantages, and the reduced risk of autologous cell therapy rejection have created new growth opportunities for the autologous cell therapy Market.
Asia Pacific is anticipated to grow at the fastest CAGR of 20.0% over the forecast period owing to the rising burden of diseases, strong research activities in autologous cell therapies, the presence of a well-established biotechnology sector, developing healthcare facilities, and growing awareness for cell therapies. For instance, in November 2018, Atara Biotherapeutics announced the results of phase 1 clinical study carried out by the company’s collaboration at the University of Queensland and QIMR Berghofer Medical Research Institute. It describes findings in progressive multiple sclerosis patients which were treated with Atara’s autologous EBV-specific T-cell immunotherapy
The market players operating in the autologous cell therapy market are undertaking strategies such as new launches, and agreement, expansion to strengthen their market presence. For instance, in June 2018, the Chiesi USA and Holostem Terapie Avanzate S.r.l mentioned that the U.S FDA has granted orphan drug designation to investigational product GPLSCDO1. It is ex-vivo expanded autologous human corneal epithelial cells used for LSCD (Limbal Stem Cell Deficiency) treatment. The company further adds that it was milestone for Chiesi USA as it continues to focus on meeting the needs of people with rare diseases. Some of the prominent players in the global autologous cell therapy market include:
BrainStorm Cell Therapeutics
Holostem Terapie Avanzate S.R.L
Pharmicell Co. Inc
Caladrius Biosciences Inc
U.S. Stem Cell Inc
Bristol Myers Squibb
Market size value in 2022
USD 5.90 billion
Revenue forecast in 2030
USD 24.31 billion
CAGR of19.4% from 2022 to 2030
Base year for estimation
Actual estimates/Historic data
2017 - 2020
2022 - 2030
Revenue in USD Million & CAGR from 2022 to 2030
Revenue forecast, company share, competitive landscape, growth factors & trends
Source, application, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Russia; Japan; China; India; Australia; South Korea; Singapore; Brazil; Mexico; Argentina; Colombia; South Africa; Saudi Arabia; UAE
Key companies profiled
BrainStorm Cell Therapeutics; Holostem Terapie Avanzate S.R.L; Pharmicell Co. Inc; Opexa Therapeutics; Caladrius Biosciences Inc; U.S. Stem Cell Inc; Lonza; Bristol Myers Squibb; Novartis; Autolus therapeutics; Tego Science; Corning Incorporated; Bio Elpida; Vericel Corporation; Catalent, Inc; Sartorius AG
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global autologous cell therapy market report based on source, application, end-use, and region:
Source Outlook (Revenue, USD Million, 2017 - 2030)
Mesenchymal Stem Cells
Haematopoietic Stem Cells
Application Outlook (Revenue, USD Million, 2017 - 2030)
End-use Outlook (Revenue, USD Million, 2017 - 2030)
Hospitals & Clinics
Academics & Research
Regional Outlook (Revenue, USD Million, 2017 - 2030)
Middle East & Africa
b. The global autologous cell therapy market size was estimated at USD 5.1 billion in 2021 and is likely to reach USD 5.9 billion in 2022.
b. The global autologous cell therapy Market is anticipated to grow at a compound annual growth rate of 19.4% from 2022 to 2030 to reach USD 24.31 billion by 2030.
b. North America dominated the market with a revenue share of around 42% in 2021 owing to the presence of key player in region and well developed biotechnology industry and burden of cancer cases in the region.
b. Key players operating in the autologous cell therapy market include BrainStorm Cell Therapeutics, Holostem Terapie Avanzate S.R.L, Pharmicell Co. Inc, Opexa Therapeutics, Caladrius Biosciences Inc, U.S. Stem Cell Inc, Lonza, Bristol Myers Squibb, Novartis, Autolus therapeutics, Tego Science, Corning Incorporated, Bio Elpida, Vericel Corporation, Catalent, Inc and Sartorius AG
b. Key factors that are driving the market growth include numerous immunological advantages, rise in the proportion of the geriatric population across the globe and reduced risk of autologous cell therapy rejection.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."